Journal Article Summary
The article investigates the effectiveness of a new levonorgestrel-releasing intrauterine system (IUS) called Levosert® in treating heavy menstrual bleeding (HMB) compared to the established product Mirena®. HMB is a common issue affecting a significant number of women, leading to potential health problems such as iron deficiency anemia. Finding effective treatments is crucial for improving women's quality of life and managing symptoms associated with excessive menstrual bleeding.
In this study, 280 non-menopausal women diagnosed with functional HMB were randomly assigned to receive either Levosert® or Mirena® for one year. The researchers measured menstrual blood loss (MBL) using a validated pictogram and assessed other health indicators like hemoglobin and ferritin levels. Results showed that both Levosert® and Mirena® significantly reduced MBL and improved hemoglobin and ferritin levels, with no significant differences in outcomes between the two groups. Both devices were similarly easy to insert, and the rates of expulsion and adverse events were comparable.
Despite the promising results, the study has limitations, including its single-blind design, which may have influenced the perceptions of the healthcare providers involved. Patients should be aware that while both IUS options are effective, individual responses may vary, and it's essential to discuss any concerns or questions with a healthcare professional. This conversation can help ensure that patients receive personalized care and understand the potential benefits and risks associated with each treatment option.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Mawet Marie, Nollevaux Fabrice, Nizet Dominique, Wijzen Fabienne, Gordenne Valérie, Tasev Niso, Segedi Dimitrije, Marinescu Bogdan, et al.. Impact of a new levonorgestrel intrauterine system, Levosert®, on heavy menstrual bleeding: results of a one-year randomised controlled trial. The European Journal of Contraception & Reproductive Health Care 2014. DOI: 10.3109/13625187.2014.894184. PMID: 24666176. PMCID: PMC4133966.
Featured Pill Pals Product
My Way (Levonorgestrel) 1.5 mg Tablet - Generic For Plan B and Morning After Pill --- Lupin Pharma --- Over The Counter
My Way (Levonorgestrel) 1.5 mg Tablet – Generic For Plan B and Morning After Pill — Lupin Pharma — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
